APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease COVID-19 in China.

  • Investigator Initiated Trial (IIT) to start in China, with an international team of experts from China, Austria, and Canada.
  • 24 patients with severe COVID-19 to be treated in a randomized, dual-arm trial with Apeiron’s ACE2 drug product APN01
  • APN01 was previously proven to be safe and well tolerated in Phase I and Phase II clinical trials
  • With its unique ACE2 approach APN01 offers an alternative treatment option to other approaches currently in development.

Press release